VJ Oncology

Changhoon Yoo (@changhoon_yoo) presents CheckMate 9DW data in #HCC. Nivolumab + ipilimumab shows durable benefit regardless of immune-mediated AEs. IMAEs in Asian pts were generally manageable, supporting consistent efficacy–toxicity balance with #Immunotherapy 🧬📊 Watch: ow.ly/gYF850YW2l4 #gism #oncology #livercancer This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Gilead Sciences (Silver) and Revolution Medicines (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Today’s the first day of #ESTRO26 and we are live in Stockholm 🇸🇪 covering the latest in radiation #oncology! Follow us to see who we’ll be interviewing over the next few days, and explore the program by visiting the official online platform 👇 estro2026.estro.org #ESTRO26 @ESTRO_RT #oncology #RadOnc

May is #bladdercancer awareness month, so visit VJOncology.com to keep up to date! Michiel Van Der Heijden reviews fast-moving advances in bladder cancer, where EV + pembrolizumab showing strong activity in metastatic & neoadjuvant settings 🩺🔬 Watch: ow.ly/vSm150YVY2M #gusm #oncology

Timothy Yap at #AACR26 presents early Phase I data on PLN-101095, a first-in-class dual αvβ8/αvβ1 integrin inhibitor ± pembrolizumab in ICI-refractory #SolidTumors. Signals of antitumor activity, immune activation & manageable safety in heavily pretreated pts 🔬🚀 Watch: ow.ly/acts50YVZtX #oncology #immunotherapy

May marks #braincancer awareness month, and at VJOncology, we bring you big updates in the field 🧠 David Giles discusses brain tumour vaccine strategies💉 from autologous “tumour-to-vaccine” approaches to reverse-engineering key immune components for next-gen platforms. This design-led path could accelerate more effective therapies in coming years 🔬🚀 Watch: ow.ly/p1Ba50YVZ4w #btsm #ITOC12

Lorenza Rimassa (@LorenzaRimassa) shares early ProvIDHe data in #Cholangiocarcinoma 🧬 Ivosidenib in IDH1-mutant CCA shows emerging signals of disease control & manageable safety in Australian 🇦🇺 & South Korean 🇰🇷 cohorts, consistent with global findings 📊🔬 Watch: ow.ly/Q9in50YW06J #gism #oncology #immunotherapy This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Gilead Sciences (Silver) and Revolution Medicines (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Ben Tran at #GU26 shares CLIMATE cohort data in #TesticularCancer, where circulating miR-371 shows strong potential as an MRD marker during active surveillance. Post-orchiectomy detection outperforms current biomarkers in predicting recurrence 📊🎯 Watch: ow.ly/RCo450YVY0r #gusm #oncology

Jesus Fuentes-Antras discusses LAG-3/PD-1 bispecifics in #Immunotherapy, where dual targeting may optimise immune synapse signalling, improve PK/PD consistency & simplify dosing. Watch: ow.ly/KRAi50YVHYm #oncology #immunotherapy

At #ELCC26, Gerard Walls (@gwalls89) highlights complexity treating #LungCancer pts with cardiac comorbidities ❤️🫁 Emphasises holistic decision-making beyond history using ECOG, 3LD, geriatric & sarcopenia assessments + ePROMs to tailor care HCPs 🎯 Watch: ow.ly/lov650YVYrk #CardioOncology #lcsm #oncology

Kristen Pauken (@kepauken) highlights key bottlenecks in irAE research inc limited pre-treatment samples, unclear links between cancer response & toxicity, and need for better translational models 🔬 Advancing #Immunotherapy safety also requires stronger preclinical systems ⚠️ Watch: ow.ly/pmfm50YVZpZ #oncology #AACR26

Gabriela Ilie at #GU26 explores digital interventions in cancer care, noting benefits of accessibility via platforms like Zoom 🌍 but stressing consistency, stability & clinician guidance. The PC-PEP model (prescription, description, demonstration) stands out for structured patient empowerment 🧠📈 Watch Watch: ow.ly/Xp0R50YVIbq #prostatecancer #gusm #oncology

Surein Arulananda reviews toxicity management with bispecific T-cell engagers like tarlatamab in #Immunotherapy, where CRS & ICANS require early recognition; CRS often occurs in first 2 weeks and is managed with antipyretics ± steroids. Watch now: ow.ly/Y3sG50YW01p #Oncology #ESMOAsia25

Brendon Stiles (@BrendonStilesMD) discusses evolving #LungCancer staging 🫁 showing stage III, including T3/T4 N2 disease, may still be resectable despite 8th ed IIIB status once considered unresectable. Decisions increasingly driven by biology & surgical judgement 🔬 Watch: ow.ly/msOH50YVYoC #lcsm #nsclc #oncology This video is available on the Lung Cancer Channel on VJOncology, an independent medical education platform, which is supported by Johnson & Johnson and Takeda. Supporters have no influence over the production of content.

Laurence Buisseret highlights advances in #BreastCancer therapy, where ADCs (T-DM1, T-DXd) and ICIs reshaping care. ASCENT data show sacituzumab govitecan + pembrolizumab as a promising first-line option in #TNBC 💉📈 Watch: ow.ly/8XB150YVHST #bscm #immunotherapy

Chris Labaki (@Chrislabaki1 ) at #GU26 highlights belzutifan monotherapy & combinations in #KidneyCancer 🧬 LITESPARK-011 shows lenvatinib + belzutifan vs cabozantinib after ICI, shaping #TKI-based algorithms & combo strategies 📊 Watch: ow.ly/48o250YVI2I #gusm #oncology

John Paul Shen (@jpshen_md) discusses challenges in #AppendixCancer, a rare disease where evidence is limited. He emphasizes transparent, patient-centred decision-making & the critical role of clinical trials to define best options for high-risk pts & advance care 📊🤝 Watch: vjoncology.com/video/9bkjsv2t… #gism #oncology #gi26 This video is available on the GI Cancer Channel on VJOncology, an independent medical education platform, which is supported by Gilead Sciences (Silver) and Revolution Medicines (Silver). Supporters have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Want to find out about the latest advances in radiation #oncology? Stay tuned for our exclusive coverage of the ESTRO 2026 Meeting taking place next week in Stockholm, Sweden! 🎥 🇸🇪 In the meantime, visit #ESTRO26's online platform to prepare for the meeting here: estro2026.estro.org @ESTRO_RT #RadOnc

Matthew Hatton #BTOG26 discusses #ThoracicOncology 🫁 in bulky disease where systemic therapy alone often fails locally, early radiotherapy may delay relapse, improve QoL & outcomes. Modern techniques (conformal RT, high-dose fractionation) expand control options 🎯 Watch: ow.ly/acO050YV9i3 #LungCancer #Oncology #NSCLC #SCLC @BTOGORG This video is available on the Lung Cancer Channel on VJOncology, an independent medical education platform, which is supported by Johnson & Johnson and Takeda. Supporters have no influence over the production of content.

Abhirup Chanda discusses how treatment response in #oncology can influence weight gain & appetite 📈 responders to systemic therapy tend to gain more weight. The true impact of agents like megestrol acetate & olanzapine remains confounded by disease status ⚖️🍽️ Watch: ow.ly/JxRL50YVZR5 #ESMOAsia25 #SupportiveCare